STOCK TITAN
  1. Home
  2. Sec-filings
  3. IOVA
  4. [Form 4] IOVANCE BIOTHERAPEUTICS, INC. Insider Trading Activity

Iovance Biotherapeutics (IOVA) COO logs RSU vesting and tax share withholding

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

IOVANCE BIOTHERAPEUTICS, INC. Chief Operating Officer Igor Bilinsky reported equity award activity tied to restricted stock units. On March 2, 2026, RSUs covering 8,790 and 3,517 shares vested and were converted into common stock at no cash exercise price. This resulted in the issuance of 12,307 shares of common stock. Separately, 6,903 shares of common stock were withheld by the company to cover mandatory tax obligations upon vesting, which the filing notes was not an open market sale. After these transactions, Bilinsky directly owned 111,148 shares of common stock.

Positive

  • None.

Negative

  • None.
Insider BILINSKY IGOR
Role Chief Operating Officer
Type Security Shares Price Value
Exercise Restricted Stock Units 8,790 $0.00 --
Exercise Restricted Stock Units 3,517 $0.00 --
Exercise Common Stock 12,307 $0.00 --
Tax Withholding Common Stock 6,903 $3.79 $26K
Holdings After Transaction: Restricted Stock Units — 35,159 shares (Direct); Common Stock — 118,051 shares (Direct)
Footnotes (1)
  1. Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. Represents common stock remaining after deducting the common stock withheld for taxes. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The remaining RSUs will vest in equal quarterly installments. Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BILINSKY IGOR
(Last) (First) (Middle)
C/O IOVANCE BIOTHERAPEUTICS, INC.
825 INDUSTRIAL ROAD, SUITE 100
(Street)
SAN CARLOS CA 94070
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Operating Officer
3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock(1) 03/02/2026 M 12,307 A $0 118,051 D
Common Stock(2) 03/02/2026 F 6,903 D $3.79 111,148(3) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (4) 03/02/2026 M 8,790 (5) (5) Common stock 8,790 $0.00 35,159(6) D
Restricted Stock Units (4) 03/02/2026 M 3,517 (5) (5) Common stock 3,517 $0.00 0(7) D
Explanation of Responses:
1. Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
2. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
3. Represents common stock remaining after deducting the common stock withheld for taxes.
4. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
5. The remaining RSUs will vest in equal quarterly installments.
6. Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person.
7. Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person.
/s/ Igor Bilinsky 03/04/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did IOVANCE BIOTHERAPEUTICS (IOVA) report for Igor Bilinsky?

The filing shows Igor Bilinsky had restricted stock units vest and convert into 12,307 common shares, with 6,903 shares withheld to cover taxes. These transactions reflect equity compensation activity, not open market buying or selling of Iovance Biotherapeutics stock.

Did IOVANCE BIOTHERAPEUTICS COO Igor Bilinsky sell IOVA shares in the open market?

No, the filing states 6,903 shares were withheld to satisfy mandatory tax withholding upon RSU vesting and were not an open market sale. This is a standard tax-settlement mechanism for equity awards rather than a discretionary sale of Iovance Biotherapeutics shares.

How many IOVANCE BIOTHERAPEUTICS shares does Igor Bilinsky own after this Form 4?

After the reported RSU vesting and tax withholding transactions, Igor Bilinsky directly owns 111,148 shares of Iovance Biotherapeutics common stock. This figure reflects the net position after converting vested restricted stock units and deducting shares withheld for associated tax obligations.

What restricted stock unit activity was disclosed for IOVANCE BIOTHERAPEUTICS (IOVA)?

Restricted stock units covering 8,790 and 3,517 shares vested for COO Igor Bilinsky on March 2, 2026. Each RSU equals one common share, so these vestings converted into common stock as part of his compensation, without an open market purchase of additional Iovance Biotherapeutics shares.

How were taxes handled on Igor Bilinsky’s RSU vesting at IOVANCE BIOTHERAPEUTICS?

To satisfy mandatory tax withholding on the RSU vesting, 6,903 shares of Iovance Biotherapeutics common stock were withheld by the company. The disclosure emphasizes this was solely for tax withholding and does not represent an open market sale transaction by Bilinsky.